FDA
-
-
-
-
-
-
-
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update
-
-
-
-
-
-
-
Spero Therapeutics (SPRO) Provides Business Update and Announces Interim Leadership Changes
-
-
-
-
-
-
-
Spero Therapeutics (SPRO) Announces Publication of SPR720 Phase 1 Lung Exposure Data
-
-
-
-
-
-
-
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
-
-
-
-
-
-
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Spero Therapeutics (SPRO) Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
-
-
-
-
-
-
-
Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

